Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
NewAmsterdam Pharma Company N.V. - Ordinary Shares
(NQ:
NAMS
)
21.78
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
15
Open
21.78
Bid (Size)
17.59 (1)
Ask (Size)
22.60 (1)
Prev. Close
21.78
Today's Range
21.78 - 21.78
52wk Range
8.640 - 26.35
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
November 06, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Performance
YTD
+82.26%
+82.26%
1 Month
+22.70%
+22.70%
3 Month
+39.08%
+39.08%
6 Month
-0.05%
-0.05%
1 Year
+113.53%
+113.53%
More News
Read More
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
October 28, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Expert Ratings For NewAmsterdam Pharma
September 23, 2024
Via
Benzinga
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
August 30, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside
August 28, 2024
Via
Benzinga
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
August 07, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Analyst Confident In NewAmsterdam Pharma's Cholesterol Drug Despite Mixed Reactions To Study Results
July 30, 2024
Via
Benzinga
Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
July 29, 2024
Via
Benzinga
NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations
July 29, 2024
Via
Investor's Business Daily
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
July 29, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
July 26, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
July 18, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
July 08, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
July 05, 2024
Via
Investor's Business Daily
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
June 11, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
May 29, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
May 21, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
May 09, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
